In 30 out of 40 planned clinical trials of new drugs at Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, the trial either did not begin at all, or the recruitment of new patients was stopped. This was reported to Izvestia by Aleksey Maschan, director of the Institute of Hematology, Immunology and Cell Technologies of Dmitry Rogachev NMRC.
According to him, due to the suspension of new trials by large international companies, Russia will begin to lag behind developed countries in terms of integrating innovative drugs into standard clinical practice. Maschan says that each year of delay will mean lagging behind by 10 years.
“At best, we will be forced to stand still, with the technologies and achievements that we already have,” the director of the Institute of Hematology, Immunology and Cell Technologies of Dmitry Rogachev NMRC believes.
As he said, Russian oncologists still participate in international conferences. However, foreign pharmaceutical companies used to sponsor such participation by 90%, but they do not do that any longer. Russian companies continue to sponsor in a reduced volume, as participation, according to Maschan, has become significantly more expensive.
